TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Average PT from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $40.67.

A number of equities analysts have issued reports on the company. JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TGTX. Private Advisor Group LLC boosted its stake in TG Therapeutics by 3.9% during the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 542 shares in the last quarter. New York State Teachers Retirement System purchased a new stake in shares of TG Therapeutics during the third quarter valued at $1,004,000. Amalgamated Bank lifted its holdings in shares of TG Therapeutics by 712.0% during the third quarter. Amalgamated Bank now owns 39,528 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 34,660 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of TG Therapeutics by 33.7% during the third quarter. Los Angeles Capital Management LLC now owns 123,401 shares of the biopharmaceutical company’s stock valued at $2,886,000 after purchasing an additional 31,124 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Up 9.2 %

NASDAQ TGTX opened at $38.44 on Wednesday. The business has a 50 day moving average price of $30.95 and a two-hundred day moving average price of $28.43. TG Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $38.58. The stock has a market cap of $5.98 billion, a PE ratio of -384.36 and a beta of 2.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. As a group, sell-side analysts predict that TG Therapeutics will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.